Skip to main content
PLOS One logoLink to PLOS One
. 2022 Mar 30;17(3):e0263784. doi: 10.1371/journal.pone.0263784

Engineering of phenylalanine dehydrogenase from Thermoactinomyces intermedius for the production of a novel homoglutamate

Muhammad Tariq 1,2, Muhammad Israr 1,*, Muslim Raza 3,*, Bashir Ahmad 1, Azizullah Azizullah 1, Shafiq Ur Rehman 1, Muhammad Faheem 4, Xinxiao Sun 2, Qipeng Yuan 2,*
Editor: Israel Silman5
PMCID: PMC8967036  PMID: 35353822

Abstract

The dramatic increase in healthcare costs has become a significant burden to this era. Many patients are unable to access medication because of the high price of drugs. Genetic engineering has made advances to increase the yield, titer, and productivity in the bio-based production of chemicals, materials of interest, and identification of innovative targets for drug discovery. Currently, the production of homoglutamate (α-Aminoadipic acid) involves petrochemical routes that are costly with low yield and often not suitable for industrial production. Here, we established the development of NADH-dependent homoglutamate by engineering NADH-dependent phenylalanine dehydrogenase (PDH) from Thermoactinomyces intermedius, which provides a novel tool for in-vivo metabolic engineering and in-vitro catalysis. Based on computational insight into the structure, we proposed the site-specific directed mutagenesis of the two important residues of PDH through docking simulations by AutoDock Vina which elucidated the binding mode of PDH with α-Ketoadipic acid and ligands. Our results demonstrated that the catalytic efficiency Km/Kcat of the final mutant Ala135Arg showed a 3-fold increase amination activity towards the ketoadipic acid as compared to the other mutant Gly114Arg, a double mutant Gly114Arg/Ala135Arg, and wild type TiPDH. Furthermore, we have introduced formate dehydrogenase as a cofactor regenerative system in this study which further made this study economically viable. Our study unfolds the possibility of biosynthesis of other non-proteinogenic amino acids that might be valuable pharmaceutical intermediaries.

Introduction

α-Aminoadipic acid also known as homoglutamate is a non-proteinogenic amino acid. It is a well-known acyclic precursor of the penicillins and cephalosporins antibiotics [1]. It is a potent prognosticator of prostate cancer [2], a biomarker for diabetes [3], a pharmacological tool as a notable inhibitory of L-glutamate uptake, and a hypothetically precarious phase in the recycling of neurotransmitter glutamate [4]. It is reported as an important intermediary metabolite in the α-aminoadipate pathway during the metabolism of lysine and saccahropine and penicillin in β-lactam-producing fungi [5]. It has also been observed as an intermediary metabolite in the catabolism of L-lysine in mammals and β-lactam-producing filamentous fungi [6]. In addition, this non-proteinogenic amino acid can be synthesized through different petro-chemical routes, which are costly due to expensive raw materials with low yield and are not suitable for industrial production [7, 8]. Growing concerns over the formation of toxic byproducts and high cost have inspired a quest to provide a biosynthetic route for α-aminoadipic acid that makes efficient use of inexpensive raw materials, renewable resources and minimizes the formation of toxic byproducts [9]. Thus metabolic engineering has made advances to increase the yield, titer, and productivity in the bio-based production of chemicals, materials of interest, and identification of innovative targets for drug invention.

In β-lactam producing bacteria, L-lysine is directly converted into 2-aminoadipic acid for cephamycin biosynthesis [7, 10]. In this case, the amino group on C-6 of the donor lysine molecule is trans-aminated to an accepter 2-ketoglutarate or another 2-ketoacid. The resulting 2-aminoadipic semialdehyde is consequently oxidized to 2-aminoadipic acid [11]. In the case of Penicillium chrysogenum, for the conversion of L-lysine into α-aminoadipic acid two different pathways are involved, the one pathway in which lysine 2-ketoglutarate reductase results in the formation of saccharopine from lysine by extracting one amino group to be used as a nitrogen source. While in the second pathway the ω-aminotransferase converts D-lysine or L-lysine into 2-aminoadipic semialdehyde and 2-aminoadipic acid (homoglutamic acid). Both enzymes are prompted by L-lysine which is negatively regulated by NH4+ ions. The ω-aminotransferase from different species uses 2-ketoacids as amino group acceptors. The most common ones are 2-ketoadipate and 2-ketoglutarate resulting directly in the development of 2-aminoadipic acid and glutamic acid [1113]. The pyruvate also has been reported as an amino acceptor in ω-aminotransferase from Pseudomonas putida and Pichia guillermondii catalyzed reactions [14, 15].

The phenylalanine dehydrogenase (PDH) enzyme was first reported from Brevibacterium sp. that catalyze the reversible deamination of L-phenylalanine to phenylpyruvate and ammonia in the presence of NAD [16]. It is also significant for the production of L-phenylalanine and its associated L-aminoacids from the corresponding Oxo-analogues and ammonia [17].

This enzyme from Bacillus badius was reported for more specific identification of phenylketonuria (PKU) disease [18]. The phenylalanine dehydrogenase from Thermoactinomyces intermedius is pro-S stereospecific for hydrogen transfer of NADH and has high substrate specificity and thermostability for amino acid biosynthesis [16]. It inherits hexapeptide segments (124F-V-H-A-A-129R) in the substrate-binding domain and is responsible for directing the most desirable substrates of the phenylpyruvate, phenyl-alanine, and phenylalanine dehydrogenase [19]. Comparison of different phenylalanine dehydrogenases has shown substantial resemblance particularly in the region between D58-E130. The region from D58 to E130 contains a 78G-G-G-81K domain, which is common in different aminoacid dehydrogenases and probably constitutes the catalytic domain [17].

In the present study, we have chosen reductive amination reaction strategies for the production of homoglutamate which is an interesting route for the conversion of 2-ketoadipic acid catalyzed by NADH-dependent phenylalanine-dehydrogenase. To our knowledge, we have reported for the first time the engineering of phenylalanine dehydrogenase enzyme in E. coli for the production of homoglutamate as shown in Scheme 1. Previously, the affinity of TiPDH towards the transamination of 2-ketoadipic acid as substrate was found insufficient. Therefore, based on computational insight into the structure of TiPDH, we proposed the site-specific directed mutagenesis of the two important residues of PDH through docking simulations by AutoDock Vina. Subsequently, it elucidated the binding mode of PDH with α-Ketoadipic acid and ligands by mutating the two important residues in the active sites of TiPDH that resulted in the production of homoglutamate. We have changed Gly114 to Arg114 and Ala135 to Arg135. The Ala135/Arg135 presented substantial performance compared to the wild-type enzyme and displayed about 3 fold increases towards the substrate. Besides we used formate dehydrogenase (FDH) in our system as a cofactor regenerative enzyme. The equilibrium of the system with co-factor regeneration abundantly considered homoglutamic acid production and CO2 as the reaction byproduct. In this case, the biocatalysts used in the reductive amination process are favorably retained to advance the sustainability of the reaction system.

Scheme 1. Biosynthesis of α-aminoadipic acid pathway.

graphic file with name pone.0263784.e001.jpg

Materials and methods

Bacterial strains, plasmids, and culture conditions

Bacterial strains and plasmids used in this study are listed in S1 Table. The pET-Duet1 backbone was used for gene cloning and plasmid construction, whereas the Escherichia coli (E. coli) BL21-DE3 strain was used for protein expression and homoglutamate production. Genomic DNA was isolated through (Invitrogen DNA Mini Kit according to manufacturer instructions) from different bacterial strains. All the primers used in this study are scheduled in S2 Table. The Luria-Bertani (LB) medium containing 10 g/L tryptone, 10 g/L NaCl, and 5 g/L yeast extract were used for inoculant preparation, protein overexpression, and cells propagation. The modified M9 medium contained M9 medium glucose 5 g/L, MOPS 2 g/L, glycerol 10 g/L, disodium hydrogen-phosphate 6 g/L, potassium dihydrogen-phosphate 3 g/L, ammonium chloride 1 g/L, sodium chloride 0.5 g/L, yeast powder 2 g/L was used for homoglutamate production. The BL21-DE3 strain was cultivated at 30°C and a suitable amount of kanamycin 50 μg/mL, ampicillin 100 μg/mL, and chloramphenicol 34 μg/mL were added to the medium when needed.

Gene cloning and mutagenesis

The His-tagged gene encoding phenylalanine dehydrogenase from Thermoactinomyces intermedius (TiPDH) (Accession # D00631), Sporosarcina ureae (SuPDH) (Accession # AB001031), and other genes encoding leucine dehydrogenase (LDH) (Accession # CAA55671), glutamate dehydrogenase (GDH) (Accession # BAD69594), meso-diaminopimelate dehydrogenase (DAPDH) (Accession # BAD40410) and formate dehydrogenase (FDH) (Accession # AIY34662) from Thermoactinomyces intermedius, Bacillus Subtilis, Symbiobacterium thermophilum, and Candida boidinii respectively were augmented by PCR from extracted genomic DNA using prime star DNA polymerase. PCR was performed under the conditions, 30 cycles for each gene, each comprising denaturation at 96°C for 1 min, 30 sec for annealing at 58°C, and polymerized for 10 min at 72°C. Briefly, genes for TiPDH, SuPDH, and Bacillus Subtilis glutamate dehydrogenase (BSGDH) were digested via restriction sites BamH1 and Xhol and DAPDH and FDH using BamH1 and Kpnl while TiPDH using EcoR1 and Xhol and subcloned into plasmid pET-Duet1. The resulting plasmids were then transformed into chemically competent E. coli strain Trans 5α.

For mutagenesis two single mutations Gly114Arg and Ala135Arg were constructed through “Splicing by overlap extension SoE PCR” using Taq DNA Polymerase in the TiPDH gene. The Ala codons GCG were replaced by CGC (Arg) and Gly codon GGC by CGC (Arg). The SoE PCR conditions were set, a total of 25 cycles, each containing denaturation at 94°C for 30 sec, annealing at 62°C for 30 sec, and polymerization at 72°C for 7 min by using for both rounds of SoE PCR. During the 1st round, the external primers were used in combination with a set of complementary pairs of oligonucleotides, which are listed in S2 Table containing the mutated codons. The resulting overlapping fragments were then purified through the gel and re-combined in the 2nd round overlap extension PCR. The resulting amplicons were digested with EcoR1/Xhol, gel purified, and then ligated at 22°C into pET Duet1 expression vector with T4-DNA ligase for 2 h. Afterward, the constructs were then confirmed by sequencing the entire open reading frame and were transformed into chemically competent E. coli BL21 (DE3) cells (Stratagene) for protein expression.

Protein expression and purification

For protein expression, a fresh colony of BL21 (DE3) with the recombinant plasmid pET-Duet1 containing His-tagged wild type or mutant gene was inoculated into a 4 mL LB media tube having ampicillin 100 μg/mL and incubated at 37°C overnight in the shaker. Then 0.5 mL overnight culture was inoculated to 100 mL LB medium containing ampicillin 100 μg/mL and incubated at 37°C in a shaker with 220 rpm. After reaching the optical density (OD600) to 0.5, culture was induced through 0.5 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) for protein expression and incubated with shaking at 37°C for the next 12 h. The fermented cells were harvested at a high-speed centrifuge at 6000 rpm for 10 min. The harvested cells were then washed with the lysis buffer and disrupted by sonication (3-sec burst with 5-sec break) for 20 min. The disrupted cell debris was separated by centrifuging at 6000 rpm for 30 min at 4°C. The resulting clean supernatant was loaded to the Ni-NTA column and the column was washed by 30, 50, 300, and 500 mM of imidazole solution respectively. The eluted samples were analyzed with 12% (w/v) SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis) whereas the protein concentration was then determined using the BCA kit according to the protein standard curve.

Preparation of crude extracts and enzyme assays

All assays were performed in triplicate at 37°C. To test the transaminase activity, the genes TiLDH, TiPDH, SuPDH, BsGDH, and DAPDH were cloned into plasmid pETduet-1, respectively and protein expression and purification were performed. The purified protein was used for in vitro activity assay. The decrease in NADH (nicotinamide adenine dinucleotide) absorption at 340 nm in reaction system was found under the following condition: 1 mL reaction mixture containing 100 mM Tris-NH4Cl buffer (pH = 8.0), 1 mM NADH, 200 μL enzyme solution and 1 mM substrate 2-ketoadipate. During the reactions reduced NADH was converted into NAD+ and absorption 340 nm was measured by ultraviolet spectrophotometer.

Homology modeling of phenylalanine dehydrogenase

The target sequence of L-phenylalanine dehydrogenase Thermoactinomyces intermedius (TiPDH) was retrieved from the UniProt database [20]. The protein structure of L-PDH from the Rhodococcus sp (PDB code: 1C1D) was designated as the best model for the TiPDH homology model building using the bioinformatics tool the “BLAST online tool” [21, 22]. The template 1C1D showed 31% sequence similarity with the target protein having the highest resolution of 1.25 Å as compared to other available structures in the PDB. Bioedit software was used for the alignment of the target sequence with the template [23]. The 3-D coordinates of the template 1C1D and alignment file were used for the construction of homology models by using MODELLER 9.12 [24]. The Swiss PDB viewer v4.1.0 was used to refine the models, [25] while GROMOS 96 force field in the Swiss PDB Viewer was implemented to refine every residue. Energy minimization was performed (500 steps of steepest descent followed by 1000 steps of the conjugate gradient) without conveying any limitation. All the residues assume a stable conformation by avoiding steric interference [26]. Several other tools were used to validate the predicted models. The stereochemical quality of the protein like geometry checks, symmetry checks, (bond lengths, chirality, torsion angles, bond angles, etc.) was checked by using the PROCHECK online tool [27]. ProSA online server and ProSA2003 [28] tool was utilized to check the fitness of sequence to structure and validation of predicted 3-D models.

Molecular docking simulations

To elucidate the binding mode of TiPDH with α-Ketoadipic acid, in silico docking simulations and substrate docking methods were carried out through AutoDock Vina software [29]. The finest model TiPDH 3-D structure was selected, visualized, and the solvent molecules from protein macro-molecule were removed through different evaluation tools as discussed. The compound α-Ketoadipic acid and phenylalanine ligands structures were prepared through both Avogadro’s and Chem sketch Softwares [30, 31]. PyRex tool was connected with AutoDock Vina [32]. The calculation of gasteiger charges and the addition of hydrogen to α-Ketoadipic acid and phenylalanine were performed. All rotatable bonds of molecules were defined by default and were allowed to rotate during the automated docking process. Both the small molecule structures and prepared protein were used to calculate energy grid maps. A grid box size of 65× 65 × 65 Å points with a grid spacing of 0.8 Å was considered focusing on the center. Various binding affinities and frequent clusters were found for α-Ketoadipic acid and the best conformers were selected due to the top-ranked cluster and lower docked free energy to perform docking analysis with the LIGPLOT+ version v.1.4.5 [33] Discovery studio visualizer version 4.0 [34], and PyMOL version 1.7.2 [35]. For authentication, the docking method was optimized through ligand (L-Phenylalanine) of the enzyme phenylalanine dehydrogenase. The structure of (L-Phenylalanine) was extracted from the binding pocket and re-docked to the TiPDH macromolecule. Two important residues (Ala135Arg and Gly114Arg) were mutated and all the docking procedure was again repeated for the macromolecule.

Microbial production of homoglutamate with 2-ketoacid

The E. coli strain BL-21 was transformed with different pET-Duet plasmids harboring both wild and mutant TiPDH. A single colony of producing strain was picked and cultivated in 4 mL LB medium with the appropriate antibiotic and grown overnight at 37°C. Subsequently, the overnight pre-inoculum was transferred to a 50 mL modified M9 medium containing an appropriate amount of antibiotics and grown for 3 h at 37°C with vigorous shaking (220 rpm). The cells were then supplemented by 1 mM 2-ketoadipate as a substrate and enzyme expression was induced by adding 0.5mM IPTG after reaching the OD600 to 0.5 and then transferred into shakers at 30°C for cultivation. The samples were taken after 12 h, 24 h, and 48 h, and cell growth was monitored by measuring the OD600. The supernatant was centrifuged at (12000 rpm for 2 min) to remove the insoluble materials. The 200 μL were filtered and then analyzed by HPLC (high-performance liquid chromatography) after the process of derivatization. Triplicate transformants were used for feeding experiments.

High-performance liquid chromatography HPLC analysis

The homoglutamate as a non-natural amino acid has no obvious ultraviolet absorption. It is mostly evaluated by the amino acid analyzer and high-performance liquid-phase derivatization. The HPLC (Shimadzu) L-3530 is equipped with a reverse Diamonsil C18 column, and a UV light detector known as an evaporative light scattering detector (ELSD) as a detector to detect the product homoglutamic acid. The mobile phase contains solvent A: pure methanol (chromatographic grade) and solvent B: 1% trifluoroacetic acid with a flow rate of 0.5 mL/min. The column temperature was set at 40°C, gas pressure 3.5 MPa, homoglutamic acid detection method using isocratic elution, the proportion of mobile phase B is 95% [36].

Results

Establishment of the recombinant strains

Five transaminase enzymes TiLDH, SuPDH, TiPDH, BsGDH, and DAPDH from different bacterial strains were screened according to the structural similarity of the substrate 2-ketoadipate for the production of Homoglutamate. These enzymes were then expressed in the pET-Duet1 plasmid and purified against the substrate for its best activity. The recombinant plasmid pET-duet1 containing the TiLDH, SuPDH, TiPDH, BsGDH, and DAPDH respectively was then transferred into E. coli BL21-DE3 and named as pETduet-1-TiLDH, pETduet-1-SuPDH, pETduet-1-TiDH, pETduet-1-BS GDH, and pETduet-1-DAPDH.

Substrate specificity

To investigate the catalytic activity of the five transaminase enzymes TiLDH, SuPDH, TiPDH, BsGDH, and DAPDH, we tested the in vitro activity of all these enzymes for the substrate 2-ketoadipic acid. The recombinant strains were cultured in the M9 medium and only the TiPDH and BsGDH showed affinity towards the substrate. The reaction system was 1 mL of Tris-NH4Cl buffer (pH = 8.0) containing 1 mM of NADH, 200 μL of enzyme solution, and 1 mM of substrate 2-ketoadipic acid. During the reaction, NADH was converted to NAD+ and NADH had maximum absorption at 340 nm. Only the phenylalanine dehydrogenase TiPDH from the actinomycetes and glutamate dehydrogenase BsGDH from Bacillus Subtilis showed the specific activity towards the substrate. The TiPDH showed the highest specific activity of 0.125 μmol/min/mg of protein as compared to the BsGDH which showed 0.008 μmol/min/mg of protein, whereas, the other recombinant strains did not show any affinity towards the substrate shown in Table 1.

Table 1. Substrate specificity of dehydrogenases.

Species Gene Specific activity (μmol/min/mg protein)
Thermoactinomyces intermedius TiPDH 0.125
Bacillus subtilis BsGDH 0.008
Thermoactinomyces intermedius TiLDH 0
Symbiobacterium thermophilum DAPDH 0
Sporosarcina ureae SuPDH 0

Engineered TiPDH showed increased Kcat/Km values on NADH

We found that the activity level of phenylalanine dehydrogenase towards the transamination of 2-ketoadipic acid was insufficient, so we first hypothesized a model and combined the substrate and enzyme by using computer modeling. To get an insight into the mutated residues Gly114/Arg114 and Ala135/Arg135 and the binding pocket of 2-ketoadipic acid, we performed a computational analysis of the enzyme. The wild-type and mutant polypeptides were constructed in the pET Duet-1 vector and then transformed into E. coli BL21-DE3 which showed identical mobilities on SDS/PAGE, demonstrating the actual mol. weight of 40.5 kDa. Thus the replacement of residues in the mutant enzymes consequently didn’t dislocate the intrinsic oligomeric structure.

The enzyme-substrate affinity (Km) value was deliberated for both wild-type TiPDH and mutated TiPDHs Thermoactinomyces intermedius at a fixed concentration of the substrate 2-ketoadipic acid after drawing Line weaver–Burk plot. The Km value of the wild-type TiPDH for the substrate was calculated to be 1.771 μM and Kcat 0.308 min-1 shown in Fig 1a whereas, for the mutated TiPDH the Km was 7.518 μM and the Kcat value was 1.37 min-1 shown in Fig 1b.

Fig 1.

Fig 1

Enzyme substrate affinity of both mutant type and wild TiPDH (A) Km and Kcat values of wild type TiPDH for the substrate 2-ketoadipic acid (B) Km and Kcat values of mutant type TiPDH for the substrate 2-ketoadipic acid (C) Km and Kcat values of wild type TiPDH for the natural substrate Phenyl Pyruvate (D) Km and Kcat values of mutant TiPDH for the substrate natural substrate Phenyl Pyruvate.

The mutagenesis was in the manifestation of mutant Ala135Arg that displayed substantial alteration compared to the wild-type enzyme. The mutant Ala135Arg showed a significant amination activity towards the substrate, which was about 3-fold high as compared to wild TiPDH, indicating that the result of site-directed mutagenesis was positive. To study the changes in the catalytic properties of the enzyme after site-directed mutagenesis, the difference between wild TiPDH and mutant type TiPDH in the catalytic optimal substrate was first studied. It was found that the natural substrate for TiPDH was phenylpyruvate. We measured the specific activity of both mutant and wild-type TiPDHs towards the natural substrate. To illustrate the enzyme activity, both the mutant and wild-type TiPDHs were expressed and purified. The kinetic considerations for activation of 2-ketoadipic acid and its native substrate phenylpyruvate were determined by checking the consumption of NADH at 340 nm. The wild type TiPDH has a Kcat value of 22.29 min-1 and Km value of 0.66 μM as shown in Fig 1c for its natural substrate phenylpyruvate, whereas, the Km value of the mutant TiPDH for phenylpyruvate was 1.2 μM and the Kcat value was 25.84 min-1 shown in Fig 1d.

Phenylpyruvate was converted to phenylalanine by transaminase TiPDH and NADH. The Km and Kcat values of the enzyme were increased but the affinity with the substrate decreased. The mutation sites convert the hydrophobic amino acids to hydrophilic amino acids, which results in a decrease in the binding affinity of the phenylpyruvate with the benzene ring of the enzyme. Based on protein structure analysis for the active site of phenylalanine dehydrogenase, an amino group of K78 hydrogen bonds to the carboxyl group of the substrate and determines the substrate specificity [37]. The mutation of alanine 135 to arginine increases the hydrophobic character hydrogen bonding of the binding pocket, which clarifies why specificity constant Km/Kcat mutant TiPDH towards 2-ketoadipic acid was 3-folds increased than that towards the native substrate phenylalanine. The Ala135Arg mutation increased the specificity constant (Kcat/Km) toward the substrate in comparison with wild type and the other mutants Phenylalanine dehydrogenase, while for Gly114Arg and double mutant Gly114Arg/Ala135Arg showed no specific activity and were inactive toward the substrate.

Optimizing the biosynthetic pathway of L-homoglutamate

The pH has a great influence on the state of ionization of basic or acidic amino acids which can lead to reformed protein recognition or an enzyme might become inactive. The alterations in pH may not only affect the shape of an enzyme but may also alter the shape or charge properties of the substrate so that either the substrate cannot bind to the active site or it cannot undergo catalysis. The optimum pH of the native enzyme TiPDH was found to be 8.4 and the temperature was 35°C. The reaction of the enzyme was allowed for 4 h at different temperatures in triplicate. The product was then tested for homoglutamate by HPLC and the conversion rate was calculated which showed that the optimum pH for transamination of 2-ketoadipic acid was 40°C and may affect the activity of transamination even at lower and higher pH. The effect of pH on the transamination reaction is shown in Fig 2a.

Fig 2.

Fig 2

Catalytic activity of wild type and mutant TiPDH to convert 2-ketoadipic acid into homoglutamate (A) Activity of TiPDH (wild and mutant types) at different pH conditions (B) Activity of TiPDH (wild and mutant types) at different temperatures.

Similarly, the enzymatic activity remained high at optimum temperature, which is beneficial to the reaction. The activity of the enzyme above or below the optimal temperature may affect the rate of the enzymatic reaction. When the temperature is too high, the enzyme may be inactive. So the temperature range was set to 25–45°C for 4 h. After HPLC analysis for Homoglutamate, the optimum temperature for mutant enzyme TiPDH was found 40°C as compared to the wild-type TiPDH as shown in Fig 2b.

Even at 45°C, there is no great effect on the activity of the TiPDH enzyme but only the conversion rate was low which shows that TiPDH has low catalytic efficiency for the non-natural substrate 2-ketoadipic acid.

Effect of adding protective agent on enzyme stability

The low conversion efficacy of transaminases reaction is due to the instability and inactivation of the mutant TiPDH enzyme. There are three leading methods to increase the stability of the enzyme, which are enzyme encapsulation, chemical modification, and immobilization [38]. In this experiment shielding mediators like PMSF, sucrose, and trehalose were selected as a protectant agent. The addition of PMSF verifies whether the enzyme is hydrolyzed during the reaction while the trehalose and sucrose play a significant part in maintaining the stability of the enzyme. The hydrogen bonds are generally believed to stabilize protein structures while helping proteins to fold. As trehalose contains a large number of hydroxyl groups, it can form hydrogen bonds with water molecules to contribute to protein stability [38, 39].

PMSF effect on enzyme stability

To stipulate the consequence of PMSF on enzymes two conditions were set. After incubating for 2h at the optimum temperature, then rapidly placed on ice to cool down, and the enzyme activity was measured while in the second condition PMSF (protease inhibitor) was added to the final concentration of 2 mM at the same temperature for 2h. The results shown in S1a Fig indicate that the residual enzyme activity decreased after the addition of PMSF. The reason may be that after the addition of PMSF in the purification process, it binds to the serine residue in the active site of the enzyme deactivating the serine hydroxyl group through an esterification process.

Effect of carbohydrates on enzymes

The enzyme protecting agents the trehalose and sucrose were added in a final concentration of 2 mM, 6 mM, and 10 mM enzyme solution in as shown in S1b Fig. The sucrose at a concentration of 2 mM showed a better effect whereas the trehalose at a concentration of 6 mM presents higher residual activity as compared to the blank sample after incubation at 40°C for 2 h. Then triplicate samples were set to measure the initial enzyme activities, two samples of sucrose with a final concentration of 2 mM and trehalose with 6 mM were added to the enzyme system and the third one was taken as control without trehalose and sucrose. The cells were incubated at 40°C and enzyme activity was determined after 8 and 12 h. The results indicate that trehalose and sucrose have protective effects on the enzyme as compared to the blank control one. After incubating for 12 h, the residual enzyme activity for trehalose was 80%, and the sucrose was 70% whereas the blank one was reduced to 40% shown in Fig 3a.

Fig 3.

Fig 3

(A) Effect of Trehalose and Sucrose on enzyme TiPDH demonstrate the protective effects in the stability of the enzyme as compared to the blank control one show 40% (B) Effect of pH on the circulatory system after some time and shows a high rate of conversion at pH 8 (C) Effect of temperature on circulatory on the system and shows about 47% conversion rate of the products (D) Effect of TiPDH and FDH on the circulatory system at different ratio of TiPDH and FDH.

When the enzyme was heated, the intermediate water molecules compete with the groups on the protein molecules to form hydrogen bonds, which cause damage to the protein structure. Although enzyme protectants can also form hydrogen bonds but have less structural damage to proteins. It is because that trehalose and sucrose have a greater hydrated volume and have been ascribed to tougher and more extensive hydrogen bonding between their hydroxyl groups and water molecules. As a result, protein denaturation in such a situation would need superfluous energy to accommodate its enlarged surface area [39]. Previously, different types of osmolytes such as sucrose, sorbitol and proline were used which improved thermostability of enzyme activity, indicting greater protective effect of osmolytes as compared to our results [40].

NADH regeneration

As NADH is a more expensive chemical and the transaminase of this experiment TiPDH consumes it during the reaction so providing them in stoichiometric amounts in the reaction system is not economically viable. For this, we introduced a coenzyme circulating system choosing formate dehydrogenase (FDH) from Candida boidinii as a cofactor regenerative enzyme for our system. The formate dehydrogenase is used to catalyze the oxidation of formate to carbon dioxide reducing the biological cofactor NAD+ by formate ions to regenerate NADH necessary for a further round of catalysis and CO2 that can be removed from the system easily. The best condition using the FDH enzyme in the reaction system was 200 μL Tris-NH4CI buffer (pH = 7–9), containing 1 mM NAD+, 1g/L 2-ketoadipate, 10 mM ammonium formate, 20 μL of mut-TiPDH and FDH, the reaction was set to 35°C. The result clarifies that the introduction of the FDH and cofactor NAD+ cycle at pH 8 system can function normally and the conversion rate is 48%. But as the pH reached 9 the conversion rate dropped rapidly as shown in Fig 3b, possibly due to the pH being too high, causing the enzyme to be reversible or irreversibly inactivated.

Effect of temperature on the circulation system

To study the effect of temperature the reaction system was designated at the optimum pH containing Tris-NH4CI buffer (pH = 8), and the reaction was carried out at 30°C, 35°C, 40°C, 45°C, and 50°C, respectively. The conversion rate of homoglutamic acid was 47% after HPLC analysis at temperature 35°C after 6h as shown in Fig 3c.

When the reaction temperature reached 50°C, the conversion rate rapidly decreased because at high temperatures the enzyme was inactive.

An optimal ratio of enzymes in the circulatory system

In the circulation system, 2-ketoadipate is catalyzed by mutant TiPDH to form homoglutamic acid while formate dehydrogenase catalyzes the formation of CO2 by formic acid. The enzyme activity and reaction rate in the two reactions are different. Therefore, the conversion rate of homoglutamate is required. To reach the maximum level, the two enzymes mutant TiPDH and FDH were selected in a ratio of 1:3, 1:1, and 3:1 at the optimum temperature and pH respectively at the intervals of 1h, 2h, 4h, and 6h. The yield was detected by HPLC and the reaction was stopped by adding 20% hydrochloric acid.

The results illustrated the ratio of the conversion of TiPDH and FDH at 1:1 was 30%, at 3:1, and 1:3 were 22% and 12% respectively after 1 h of the reaction as shown in Fig 3d.

With the extension of time, the conversion rate of 1:3 TiPDH and FDH rapidly increased and reached the highest level of 53% in 6h whereas, the TiPDH and FDH 1:3 increased slowly and the conversion rate was 40% after 6h. The reason may be that the reaction rate of transaminase TiPDH is lower than that of formate dehydrogenase (FDH) and the reaction rate further decrease when the amount of transaminase enzyme decreased.

Structural stability and residual flexibility analysis of the wild type and mutant complexes

Dynamics stability of both the complexes was evaluated by calculated the Root mean square deviation (RMSD). A 20ns trajectory analysis revealed that the mutant structure remained more stable than the wild type. In case of the wild type the RMSD remained higher initially until 10ns. However, after 10ns the RMSD decreased and no major convergence was observed. The average RMSD for the wild type was reported to be 1.5Å. In case of the mutant type the RMSD remained stable and no convergence was reported. The average RMSD for the mutant was reported to be 1.0 Å. RMSDs of the wild and mutant is given in Fig 4a.

Fig 4.

Fig 4

(A) showing the RMSDs of the both complexes, (B) showing the RMSFs of the complexes. Each complex is colored differently.

To determine the residual flexibility of each systems Root mean square fluctuation (RMSF) was calculated. It can be seen that both the systems showed similar pattern of flexibility except in some regions where the wild type possess higher flexibility. These results significantly suggest that the mutants favours the binding of the substrate than the wild type and remained more stable during the simulation. RMSDs of the wild and mutant is given in Fig 4b.

To further understand the impact of the double mutant on the binding of the substrate, Gibbs free energy was calculated. Each energy term such as Van der Waal, electrostatic and the total binding energy was calculated. As given in table X the double arginine substitution favors the binding of the substrate than the wild type. The total binding energy for wild type was reported to be -34.1124 kcal/mol while for the mutant complex it was reported to be -43.6183kcal/mol. The other energy terms are given in Table 2.

Table 2. The binding free energy of the wild and mutant complexes.

All the energies are given in kcal/mol.

System vdW Electrostatic SASA Total Binding
Wild Type -20.55 -08.18 -2.3672 -34.1124
Mutant Type -23.84 -15.65 -4.8472 -43.6183

Discussion

In this work, we met with some challenges: first the genetically stable framework of the host micro-organism to grow at minimal growth conditions. To overcome this problem, we choose Escherichia coli as a model organism due to simple genetic manipulation, clear genetic background, and one of the prominent microorganisms used in metabolic engineering [41]. Its metabolism and regulation is well characterized and has a variety of genetic tools [42] like Keio knockout collection and MAGE [43], synthetic biology tools like promoters, well-characterized regulators and ribosome-binding sites [43], and systems biology tools like genome-scale models [44]. The second challenge was the use of cofactor NADH which is an expensive chemical while using a stoichiometric amount in a chemical reaction. We used FDH formate dehydrogenase from Candida boidinii in our system as a cofactor regenerative enzyme. The FDH catalyzes the oxidation of formate to CO2 with parallel reduction of biological cofactor NAD by formate ions to regenerate NADH [45, 46]. The third challenge was the stability of our mutant phenylalanine dehydrogenase enzyme (TiPDH), so we chose shielding mediators like PMSF, sucrose and trehalose as protectant stabilizers.

In the current study, we engineered the phenylalanine dehydrogenase enzyme (TiPDH) to obtain the high yield of novel non-proteinogenic homoglutamate. For this, we built the 3D homology model of TiPDH through the BLAST tool and MODELLER 9.12 as shown in Fig 5a and then analyzed its binding pocket through docking simulations. We have selected the enzyme structure from Rhodococcus sp (PDB code: 1C1D) as a template because the structure and catalytic mechanism have already been reported and provide a key basis for important amino acid residues for mutagenesis. The predicted docked pose of the TiPDH revealed that the α-Ketoadipic acid used in this study showed a promising interaction of the TiPDH enzyme. The best docking geometries of α-Ketoadipic acid and L-Phenylalanine with the most favorable binding affinities are illustrated in Fig 6a and S3 Table.

Fig 5.

Fig 5

(a) Predicted structure of TiPDH through homology modeling with 1C1D (b) Docked pose of mutant TiPDH in which the Arg114 and Arg135 best fitted in the pocket. (c) Docked pose of wild type TiPDH.

Fig 6.

Fig 6

(a) Illustration of the predicted docked poses of wild type TiPDH against the α-Ketoadipic acid (red color ball and stick) and the phenylalanine (green color sticks) while the ligand shown by the cyan color sticks (b) The 2D and 3D representation of the natural substrate (Phenylalanine) in the binding pocket of wild type TiPDH enzyme (c) The 2D and 3D representation of docked α-Ketoadipic acid (our substrate) in the binding pocket of wild type TiPDH enzyme.

The TiPDH contains two domains separated by a deep cleft. The residues 13–133 comprise N terminal containing three helices motifs and six β-stranded sheets. The residues 200–353 forming C-terminal that comprise five β-stranded sheets core surrounded by seven α-helices and one 310 helix shown in S2 Fig. The residues 78G, 79G, 80G, and 81K motif are conserved in various dehydrogenases. The lysine 81K in this glycine-rich region participates in the catalysis forming the Schiff base with α-ketoacids. The D69 and N264 are conserved and formed hydrogen bonding with the carboxylic group of the substrate. Besides these, the residues R45, D116, and T151 are also conserved and are responsible for the binding of cofactor NAD (P) +. The tertiary structure of the coenzyme binding domain of NAD (P) + dehydrogenase contains four-stranded parallel β sheets and an α-helix with an essentially indistinguishable arrangement and is highly conserved [17].

We observed that the functional moieties of these molecules play an important role in the interactions. Molecular insights based on simulation revealed the reason behind the higher activity of α-Ketoadipic acid. The ligand L-Phenylalanine showed important interactions with the crucial moieties in the substrate-binding pocket as shown in Fig 6b.

The Asn264 interacts with the carboxyl moiety through hydrogen bonding with a distance of 2.97Å, similarly, also Thr115 interacts with an amino group formed hydrogen bonding with a bond length of 2.98Å. Besides, these favorable contacts there are also other sensible hydrophobic interactions observed from the surrounding pocket, like Leu41, Gly42, Gly43, Met66, Lys69, Gly114, and Leu294. Furthermore, it should be noted that the terminal carboxylic functional moieties of α-Ketoadipic acid significantly interact through three hydrogen bonding with the important residues such as Gly145 (2.80 Å), Thr147 (2.92 Å) and Gly293 (2.79 Å). It should be noteworthy, that there are around nine hydrophobic contacts that were detected in the binding pocket of α-Ketoadipic acid including Gly114, Thr115, Ala135, Gly136, Lys144, Asp146, Gln296, Val297, and Glu300 Fig 6c.

Phenylalanine dehydrogenases from different enzymes have shown substantial resemblance particularly in the region between D58-E130. The region from D58 to E130 contains a 78G-G-G-81K domain, which is common in different aminoacid dehydrogenases and probably constitutes the catalytic domain [17].

Based on computational insight to the structure, we proposed that the site-specific directed mutagenesis of the two important residues in the predicted binding pocket of α-Ketoadipic acid Gly114/Arg114 and Ala135/Arg135 led to the major reason showing the stronger affinity and was best fitted inside the binding pocket Fig 5b and 5c, and resulted in the best activity.

It was strongly supported through significant two hydrogen-bonding interactions by mutated Arg114 (2.93 Å and 2.73 Å) with the α-Ketoadipic acid while the wild type Gly114 only showed hydrophobic interactions. Additionally, in the wild type Ala135 formed only hydrophobic interactions while the mutated Arg135 formed one hydrogen bonding with the α-Ketoadipic acid Fig 7a and 7b.

Fig 7. The 2D illustration of the docked pose of α-Ketoadipic acid in the binding pocket of the TiPDH enzyme.

Fig 7

(a) The pose of α ketoadipic acid with wild type TiPDH (b) Pose of α-Ketoadipic acid with the mutated TiPDH.

Furthermore, the structural interactions of both α-Ketoadipic acid and L-Phenylalanine showed the most favorable electrostatic interactions with the active site of the enzyme but the shape and steric bulk will be the limiting factor in the biological conversion of α-Ketoadipic acid and L-Phenylalanine. The L-Phenylalanine was found to have a lesser affinity because its molecular size and weak interactions could create a barrier towards its binding inside the active site of the enzyme.

Conclusions

In the summary, two single Ala135Arg, Gly114Arg, and one double Gly114Arg/Ala135Arg mutation in TiPDH were carried out for the amination of ketoadipic acid. The catalytic efficiency Km/Kcat of the mutant Ala135Arg showed a 3-fold increase towards the ketoadipic acid as compared to the other mutant Gly114Arg, a double mutant Gly114Arg/Ala135Arg, and wild type TiPDH. Besides, the formate dehydrogenase (FDH) in the system was applied as a cofactor regenerative enzyme to make the system economically viable. Some of the shielding mediators like PMSF, sucrose, and trehalose were chosen as a protectant in the system to maintain the stability of the enzyme. Our study contributes to the expansion of the synthetic scope of phenylalanine dehydrogenases catalyzed asymmetric reductive amination and unfolding the possibility of biosynthesis of other non-proteinogenic amino acids that might be valuable pharmaceutical intermediaries.

Supporting information

S1 Fig

(a) Effect of PMSF on substrate decreased the residual enzyme activity. (b) Effect of different concentration of Trehalose and Sucrose showed protective effects in the stability of the enzyme.

(DOCX)

S2 Fig. TiPDH sequence containing thirteen α helices and twelve β strands sheets and some conserved regions.

The red underlined K69, K81, and N264 are conserved residues and are involved in the binding of substrate. Whereas the highlighted residues encircled in the red boxes are involved in the binding of cofactors.

(DOCX)

S1 Table. Plasmids used in this work.

(DOCX)

S2 Table. Primers for wild type and mutant enzymes used in this study.

(DOCX)

S3 Table. Molecular docking statistics of α-Ketoadipic acid and Phenylalanine with the binding pocket of TiPDH.

(DOCX)

Acknowledgments

All the authors are grateful to Dr. Muhammad Asim Department of Biology, The University of Haripur for his constructive suggestions and help throughout manuscript writing.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Data Availability

All relevant data are within the paper and its Supporting information files.

Funding Statement

The author(s) received no specific funding for this work.

References

  • 1.Madduri K, Stuttard C, Vining L. Lysine catabolism in Streptomyces spp. is primarily through cadaverine: beta-lactam producers also make alpha-aminoadipate. Journal of Bacteriology. 1989; 171(1):299–302. doi: 10.1128/jb.171.1.299-302.1989 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Jung K, Reszka R, Kamlage B, Bethan B, Stephan C, Lein M, et al. Tissue metabolite profiling identifies differentiating and prognostic biomarkers for prostate carcinoma. International Journal of Cancer. 2013; 133(12):2914–2924. doi: 10.1002/ijc.28303 [DOI] [PubMed] [Google Scholar]
  • 3.Wang TJ, Ngo D, Psychogios N, Dejam A, Larson MG, Vasan RS, et al. 2-Aminoadipic acid is a biomarker for diabetes risk. Journal of Clinical Investigation. 2013; 123(10):4309–4317. doi: 10.1172/JCI64801 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Fykse EM, Iversen EG, Fonnum F. Inhibition of L-glutamate uptake into synaptic vesicles. Neuroscience Letters. 1992; 135(1):125–128. doi: 10.1016/0304-3940(92)90151-v [DOI] [PubMed] [Google Scholar]
  • 5.Xu H, Andi B, Qian J, West AH, Cook PF. The α-aminoadipate pathway for lysine biosynthesis in fungi. Cell Biochemistry and Biophysics.2006; 46(1):43–64. doi: 10.1385/CBB:46:1:43 [DOI] [PubMed] [Google Scholar]
  • 6.Esmahan C, Alvarez E, Montenegro E, Martin JF. Catabolism of lysine in Penicillium chrysogenum leads to the formation of 2-aminoadipic acid, a precursor of penicillin biosynthesis. Applied and Environmental Microbiology. 1994; 60(6):1705–1710. doi: 10.1128/aem.60.6.1705-1710.1994 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Coque J, Liras P, Laiz L, Martín JF. A gene encoding lysine 6-aminotransferase, which forms the beta-lactam precursor alpha-aminoadipic acid, is located in the cluster of cephamycin biosynthetic genes in Nocardia lactamdurans. Journal of Bacteriology. 1991; 173(19):6258–6264. doi: 10.1128/jb.173.19.6258-6264.1991 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Luengo JM, Revilla G, Villanueva JR, Martin JF. Lysine regulation of penicillin biosynthesis in low-producing and industrial strains of Penicillium chrysogenum. Journal of Microbiology. 1979; 115(1):207–211. doi: 10.1099/00221287-115-1-207 [DOI] [PubMed] [Google Scholar]
  • 9.Brakhage AA, Turner G L-lysine repression of penicillin biosynthesis and the expression of penicillin biosynthesis genes acvA and ipnA in Aspergillus nidulans. FEMS Microbiology Letters. 1992; 98(1–3):123–127. [DOI] [PubMed] [Google Scholar]
  • 10.Madduri K, Shapiro S, DeMarco A, White R, Stuttard C, Vining L. Lysine catabolism and α-aminoadipate synthesis in Streptomyces clavuligerus. Applied microbiology and biotechnology. 1991; 35(3):358–363. doi: 10.1007/BF00172726 [DOI] [PubMed] [Google Scholar]
  • 11.De Valmaseda EM, Campoy S, Naranjo L., Casqueiro J, Martín JF. Lysine is catabolized to 2-aminoadipic acid in Penicillium chrysogenum by an omega-aminotransferase and to saccharopine by a lysine 2-ketoglutarate reductase. Characterization of the omega-aminotransferase. Mol Gen Genomics. 2005; 274(3): 272–282. [DOI] [PubMed] [Google Scholar]
  • 12.Kern B, Hendlin D, Inamine E. L-lysine epsilon-aminotransferase involved in cephamycin C synthesis in Streptomyces lactamdurans. AntimicrobialAgents and Chemotherapy. 1980; 17(4):679–685. doi: 10.1128/AAC.17.4.679 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Kinzel J, Winston M, Bhattacharjee J. Role of L-lysine-alpha-ketoglutarate aminotransferase in the catabolism of lysine as a nitrogen source for Rhodotorula glutinis. Journal of Bacteriology. 1983; 155(1):417–419. doi: 10.1128/jb.155.1.417-419.1983 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Schmidt H, Bode R, Birnbaum D. A novel enzyme, L-lysine: pyruvate aminotransferase, catalyses the first step of lysine catabolism in Pichia guilliermondii. FEMS Microbiology Letters.1988; 49(2):203–206. [Google Scholar]
  • 15.Yonaha K, Nishie M, Aibara S. The primary structure of omega-amino acid: pyruvate aminotransferase. Journal of Biological Chemistry. 1992; 267(18):12506–12510. [PubMed] [Google Scholar]
  • 16.Ohshima T, Takada H, Yoshimura T, Esaki N, Soda K. Distribution, purification, and characterization of thermostable phenylalanine dehydrogenase from thermophilic actinomycetes. Journal of Bacteriology 1991;173(13):3943–3948 doi: 10.1128/jb.173.13.3943-3948.1991 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Takada H, Yoshimura T, Ohshima T, Esaki N, Soda K Thermostable phenylalanine dehydrogenase of Thermoactinomyces intermedius: cloning, expression, and sequencing of its gene. Journal of Biochemistry. 1991; 109(3):371–376. doi: 10.1093/oxfordjournals.jbchem.a123388 [DOI] [PubMed] [Google Scholar]
  • 18.Yousefi F, Ataei F, Arab SS, Hosseinkhani S. Increase of Bacillus badius Phenylalanine dehydrogenase specificity towards phenylalanine substrate by site-directed mutagenesis. Archives of biochemistry and biophysics. 2017; 635:44–51. doi: 10.1016/j.abb.2017.10.009 [DOI] [PubMed] [Google Scholar]
  • 19.Kataoka K, Takada H, Yoshimura T, Furuyoshi S, Esaki N, Ohshima T, et al. Site-directed mutagenesis of a hexapeptide segment involved in substrate recognition of phenylalanine dehydrogenase from Thermoactinomyces intermedius. Journal of Biochemistry. 1993; 114(1):69–75. doi: 10.1093/oxfordjournals.jbchem.a124142 [DOI] [PubMed] [Google Scholar]
  • 20.DeLano WL. PyMOL. DeLano Scientific, San Carlos, CA. 2002; 700. [Google Scholar]
  • 21.Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ Basic local alignment search tool. Journal of Molecular Biology. 1990;215(3):403–410 doi: 10.1016/S0022-2836(05)80360-2 [DOI] [PubMed] [Google Scholar]
  • 22.Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat T, Weissig H, et al. The protein data bank. Nucleic Acids Research. 2000; 28(1):235–242 doi: 10.1093/nar/28.1.235 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Hall TA. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. In: Nucleic Acids Symp. Ser 1999. vol 41. p 95–98 [Google Scholar]
  • 24.Eswar N, Eramian D, Webb B, Shen M-Y, Sali A. Protein structure modeling with MODELLER Structural Proteomics. Springer, 2008;145–159 [DOI] [PubMed] [Google Scholar]
  • 25.Guex N, Peitsch MC. SWISS-MODEL and the Swiss-Pdb Viewer: an environment for comparative protein modeling. Journal of Electrophoresis. 1997; 18(15):2714–2723 doi: 10.1002/elps.1150181505 [DOI] [PubMed] [Google Scholar]
  • 26.Kaplan W, Littlejohn TG. Swiss-PDB viewer (deep view). Briefings in Bioinformatics. 2001;2(2):195–197. doi: 10.1093/bib/2.2.195 [DOI] [PubMed] [Google Scholar]
  • 27.Laskowski R, MacArthur M, Thornton J. PROCHECK: Validation of protein structure coordinates 2002
  • 28.Wiederstein M, Sippl MJ. ProSA-web: interactive web service for the recognition of errors in three-dimensional structures of proteins. Nucleic Acids Research. 2007; 35(suppl 2): W407–W410. doi: 10.1093/nar/gkm290 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. Journal of Computational Chemistry. 2010;31(2):455–461. doi: 10.1002/jcc.21334 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Hanwell MD, Curtis DE, Lonie DC, Vandermeersch T, Zurek E, Hutchison GR. Avogadro: an advanced semantic chemical editor, visualization, and analysis platform. Journal of cheminformatics. 2012; 4(1):17. doi: 10.1186/1758-2946-4-17 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Li Z, Wan H, Shi Y, Ouyang P. Personal experience with four kinds of chemical structure drawing software: review on ChemDraw, ChemWindow, ISIS/Draw, and ChemSketch. Journal of Chemical Information and Computer Science. 2004; 44(5):1886–1890. [DOI] [PubMed] [Google Scholar]
  • 32.Wargasetia TL, Permana S, Widodo N. Potential use of compounds from sea cucumbers as MDM2 and CXCR4 inhibitors to control cancer cell growth. Experimental and therapeutic Medicine 2018;16(4):2985–2991. doi: 10.3892/etm.2018.6588 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Laskowski RA, Swindells MB. LigPlot+: multiple ligand-protein interaction diagrams for drug discovery. ACS Publications. 2011. [DOI] [PubMed] [Google Scholar]
  • 34.Umamaheswari M, Madeswaran A, Asokkumar K, Sivashanmugam T, Subhadradevi V, Jagannath P. Discovery of potential xanthine oxidase inhibitors using in silico docking studies. Der pharma chemica 2011; 3(5):240–7. [Google Scholar]
  • 35.Pymol T (2010) The PyMOL molecular graphics system. Version
  • 36.Sun J, Ren Y, Raza M, Sun X, Yuan Q. Microbial production of glutaconic acid via extradiol ring cleavage of catechol. Journal of Chemical Technology and Biotechnology. 2018; 93(6):1677–1683. [Google Scholar]
  • 37.Seah SY, Britton KL, Rice DW, Asano Y, Engel PC. Kinetic analysis of phenylalanine dehydrogenase mutants designed for aliphatic amino acid dehydrogenase activity with guidance from homology-based modeling. European Journal of Biochemistry. 2003; 270(23):4628–4634. doi: 10.1046/j.1432-1033.2003.03852.x [DOI] [PubMed] [Google Scholar]
  • 38.Azizi A, Ranjbar B, Khajeh K, Ghodselahi T, Hoornam S, Mobasheri H, et al. Effects of trehalose and sorbitol on the activity and structure of Pseudomonas cepacia lipase: spectroscopic insight. International Journal of Biological Macromoles. 2011; 49(4):652–656. [DOI] [PubMed] [Google Scholar]
  • 39.Leslie SB, Israeli E, Lighthart B, Crowe JH, Crowe LM. Trehalose and sucrose protect both membranes and proteins in intact bacteria during drying. Appl Environ Microbiol 1995; 61(10):3592–3597. doi: 10.1128/aem.61.10.3592-3597.1995 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Mehrabi M, Hosseinkhani S, Ghobadi S. Stabilization of firefly luciferase against thermal stress by osmolytes. International journal of biological macromolecules. 2008; 43(2):187–91. doi: 10.1016/j.ijbiomac.2008.05.001 [DOI] [PubMed] [Google Scholar]
  • 41.Liu X, Niu H, Li Q, Gu P. Metabolic engineering for the production of l-phenylalanine in Escherichia coli. 3 Biotechnology.2019;9(3):85. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Wang HH, Isaacs FJ, Carr PA, Sun ZZ, Xu G, Forest CR, et al. Programming cells by multiplex genome engineering and accelerated evolution. Nature. 2009; 460(7257):894. doi: 10.1038/nature08187 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Baba T, Ara T, Hasegawa M, Takai Y, Okumura Y, Baba M, et al. Construction of Escherichia coli K-12 in-frame, single-gene knockout mutants: the Keio collection. Molecular Systems Biology.2006;2(1). doi: 10.1038/msb4100050 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Zhang X, Tervo CJ, Reed JL Metabolic assessment of E. coli as a biofactory for commercial products. Metabolic Engineering. 2016; 35:64–74. doi: 10.1016/j.ymben.2016.01.007 [DOI] [PubMed] [Google Scholar]
  • 45.Politino M, Cadin M, Skonezny P, Chen J. Process for preparing dipeptidyl IV inhibitors and intermediates therefor. WO Patent. 2005106011. 2005.
  • 46.Shaked Ze, Whitesides GM. Enzyme-catalyzed organic synthesis: NADH regeneration by using formate dehydrogenase. Journal of the American Chemical Society. 1980; 102(23):7104–7105. [Google Scholar]

Decision Letter 0

Israel Silman

23 Aug 2021

PONE-D-21-21697

Engineering of Phenylalanine Dehydrogenase from Thermoactinomyces Intermedius for the Production of a novel Homoglutamate

PLOS ONE

Dear Dr. Israr,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please address as fully as possible the comments of both reviewers, especially the detailed and constructive comment of Reviewer 2.

Please submit your revised manuscript by Oct 07 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Israel Silman

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. We note that you have included the phrase “data not shown” in your manuscript. Unfortunately, this does not meet our data sharing requirements. PLOS does not permit references to inaccessible data. We require that authors provide all relevant data within the paper, Supporting Information files, or in an acceptable, public repository. Please add a citation to support this phrase or upload the data that corresponds with these findings to a stable repository (such as Figshare or Dryad) and provide and URLs, DOIs, or accession numbers that may be used to access these data. Or, if the data are not a core part of the research being presented in your study, we ask that you remove the phrase that refers to these data.

3. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: No

Reviewer #2: N/A

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: No

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: 1. The whole data re suffering from lack of sufficient statistical analysis, it should be added more emphasized on kinetic data.

2. I am not sure about kcat/km and km/kcat difference? i presume they are the same and should be corrected in the whole manuscript.

3. Is there any data regarding specificity of native and mutant enzymes towards Tyrosine compared phenylalanine. Based on whatever reported in the literature it should be at least be discussed, as reported in:

Archives of Biochemistry and Biophysics

Volume 635, 1 December 2017, Pages 44-51.

4. Kcat/Km ratio also should be shown in table.

5. in the literature review , i presume similar papers on the effect of enzyme stabilizers could be used:

-International Journal of Biological Macromolecules, Volume 43, Issue 2, 15 August 2008, Pages 187-191.

-Journal of Molecular Catalysis B: Enzymatic

Volume 62, Issue 2, February 2010, Pages 127-132

Reviewer #2: General Comments

The work “Engineering of phenylalanine dehydrogenase…” PONE D 21 21697, by Tariq et al. is dedicated to the design of an enzymatic system to obtain the non-proteinogenic amino acid homoglutamate. This compound may have medical interest and is usually known as alpha aminoadipic acid (AAA). In the Introduction the authors describe several AAA biosynthetic methods that may be used to obtain this compound; however, they do not focus the article on the use of the naturally producing AAA biosynthetic enzymes, the names of which are not cited. These enzymes are present in actinobacteria or fungi and are well known to form AAA as precursor of the beta-lactam antibiotics. Instead, the authors choose to study the phenylalanine dehydrogenase of Thermoactinomyces intermedius an enzyme that, as the authors indicate in line 336, lacks efficiency for the amination of alpha ketoadipic acid, the compound used by the authors as substrate. Therefore, it is surprising that the authors choose to modify the phenylalanine DH which belong to type I (aromatic) aminotransferases to develop this project. The experimental part of the work dedicated to the modification of the T intermedius PDH is largely correct although there are some obscure points in the quantification method as indicated below. The authors also studied the regeneration of NADH cofactor for the TiPDH by using the well known formate DH (decarboxylase) that produces NADH. The discussion is entirely focused on the modification of the protein that the authors have performed but they fail to discuss the main aim of this project which is the microbial production of AAA by microbial biosynthetic methods which are easy and highly productive.

Specific comments

1. In the abstract the authors refer to the compound of interest as homoglutamate; however, this compound is usually named 2-aminoadipic acid or alpha aminoadipic acid. Please, use at least in the abstract the two names, so that the readers can identify the compound that is being investigated as you have done in the first sentence of Introduction.

2. In lines 55 the authors indicate that homoglutamate is a putative acyclic precursor of penicillins an cephalosporins. This word “putative” in this sentence is misleading; it is very well stablished in numerous articles that alpha aminoadipate (AAA) is a real precursor of penicillins and of cephalosporin C in P. chrysogenum and C. acremonium, respectively. Please clarify this point eliminating the word “putative” and providing more recent references. Also provide information on the enzymes producing AAA in actinobacteria and fungi.

3. In lines 69-70 it is indicated that there is no native pathway for the biosynthesis of alpha aminoadipate. This sentence is wrong; it is well known that there are pathways for AAA which are different in distinct microorganisms as actinobacteria and filamentous fungi. Please modify the sentence

4. In line 73 that authors state that AAA is an intermediate in the catabolism of lysine in mammals and in beta-lactam producing actinomycetes (Esmahan et al 1994). The work of Esmahan was made in filamentous fungi not in actinomycetes. This is an important microbiological mistake since actinomycetes are bacteria.

5. Lines 73-76. The authors say “However, this non proteinogenic amino can be…”. Please correct amino to amino acid. The term “however” is not adequate since it means that there is a contradiction with the previous sentence, which is not the case. Change the term “however” to “in addition…”. Please correct also the reference of Luengo et al in line 76 and in the references list.

6. Lines 93-95 the �-aminotransferase reaction which convert the alpha ketoadipic acid is into alpha amino adipic acid is probably the best approach to obtain unexpensive AAA- The mechanism of action of the � aminotransferase is still poorly known but could be explored

7. In the second part of the introduction the author propos to use the phenylalanine dehydrogenase from Thermoctinomyces to produce AAA from alpha cetoadipic. This is a surprising approach since the substrate of phenylalanine DH has a 9 carbons aromatic substrate that is deaminate to phenylpyruvate; this rection biochemically is quite different from that converting alpha-ketoadipate in AAA. The authors should clarify why they choose to use this reaction for the conversion but they do not approach the modification of enzymes related to the bacterial or fungal formation of AAA. The authors should give a clear study of the relative efficiency of AAA formation by the phenylalanine DH in relation to the natural enzymes forming AAA.

8. Line 118 and in the Results section the authors indicate that the affinity of the TiPDH for transamination of the 2-cetoadipate substrate is insufficient and therefore they try to improve the production by mutagenesis of two amino acids of the putative active center. This observation indicates that this is not the best starting point for the development of the high production of AAA.

9. In Materials and Methods the authors describe the quantification of AAA formation by HPLC but, as the authors indicate previously, homoglutamate (AAA) has not good UV absortion and the method utilized is not clear. In all classical studies amino acids are measured after derivatization with OPA or other UV emitting agent. Please indicate which is the method used in this article.

10. In the Discussion section the authors focus the discussion in the structure of the TiPDH and but they do not compare the active center of this enzyme with those of other alpha aminoadipic forming enzymes.

11. The authors in line 142 give the accession number of the nucleotides sequence of the TiPDH encoding gene, D00631. However, since in the article the authors constantly refer to the TiPDH protein the accession number of the protein should be easily accessible in the text. We found that the amino acids sequence shown in figure S2 does not corresponds to the sequences published by Ohshima et al or Tanaka et al. Is a different protein?. Please clarify.

12. In line 87 the authors refer to the work of Perez Llarena refering to an enzymatic reaction. This work is purely a description of gene sequences. The real work of purification and characterization of the enzyme in that of “de la Fuente et al., 1997”

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Attachment

Submitted filename: Evaluation AAA.docx

PLoS One. 2022 Mar 30;17(3):e0263784. doi: 10.1371/journal.pone.0263784.r002

Author response to Decision Letter 0


20 Dec 2021

Dear editor

We would like thanks to you and reviewers for their precious time to review our manuscript in deep and critically and for suggesting corrections that improved the quality of our manuscript. We are pleased to submit the revised manuscript entitled “Engineering of Phenylalanine Dehydrogenase from Thermoactinomyces Intermedius for the Production of a novel Homoglutamate” for consideration in PLOS ONE. On the following pages, you will find our response to the reviewer comments. The reviewer comments and suggestions are highlighted with red color and responses to each point with normal text. On behalf of my co-authors, I thank you for your consideration of this resubmission. We appreciate your time and look forward to your response.

Sincerely,

Dr. Muhammad Israr PhD, Postdoc (Corresponding Author)

Associate Professor, Department of Biology

The University of Haripur, KPK, Pakistan

Reviewers comments and Responses

Reviewer

Comment 1: In the abstract, the authors refer to the compound of interest as homoglutamate; however, this compound is usually named 2-aminoadipic acid or alpha aminoadipic acid. Please, use at least in the abstract the two names, so that the readers can identify the compound that is being investigated as you have done in the first sentence of the Introduction.

Response 1: We are grateful to the reviewer for taking his precious time to deeply review our manuscript which enhanced its quality.

Following the reviewer's suggestion, we have added two names of 2-aminoadipic acid in the Abstract section.

Comment 2:

Abstract: In line 55 the authors indicate that homoglutamate is a putative acyclic precursor of penicillins and cephalosporins. The word “putative” in this sentence is misleading; it is very well established in numerous articles that alpha aminoadipate (AAA) is a real precursor of penicillins and of cephalosporin C in P. chrysogenum and C. acremonium, respectively. Please clarify this point by eliminating the word “putative” and providing more recent references. Also, provide information on the enzymes producing AAA in actinobacteria and fungi.

Response 2: Thanks for this comment and suggestions. Yes, we are agreeing with the reviewer, the word “Putative” was replaced with “Well-known” as suggested by the reviewer and highlighted with red color in the track changes.

Comment 3:

In lines 69-70 it is indicated that there is no native pathway for the biosynthesis of alpha aminoadipate. This sentence is wrong; it is well known that there are pathways for AAA which are different in distinct microorganisms as actinobacteria and filamentous fungi. Please modify the sentence

Response 3: We are obliged to the reviewer for this comment and agree with his suggestion for correction. The sentence is modified and highlighted with red color in the track changes.

Comment 4:

In line 73 the authors state that AAA is an intermediate in the catabolism of lysine in mammals and beta-lactam producing actinomycetes (Esmahan et al 1994). The work of Esmahan was made in filamentous fungi, not in actinomycetes. This is an important microbiological mistake since actinomycetes are bacteria.

Response 4: We are grateful to the reviewer for pointing out this mistake. In the track changes, the sentence is corrected and the word “actinomycetes” is replaced with “Filamentous fungi” which is the work of Esmahan et al 1994.

Comment 5:

Lines 73-76. The authors say “However, this nonproteinogenic amino can be…”. Please correct amino to an amino acid. The term “however” is not adequate since it means that there is a contradiction with the previous sentence, which is not the case. Change the term “however” to “in addition…”. Please correct also the reference of Luengo et al in line 76 and the references list.

Response 5: We are grateful to the reviewer for this comment. The sentence and reference are modified accordingly and highlighted with red color in track changes.

Comment 6:

Lines 93-95 the ω-aminotransferase reaction which converts the alpha ketoadipic acid is into alpha-amino adipic acid is probably the best approach to obtain unexpansive AAA- The mechanism of action of the ω- aminotransferase is still poorly known but could be explored

Response 6: We are obliged to the reviewer for this comment. In some organisms (bacteria/fungi) the L-Lysine is converted into α-aminoadipic acid by two different pathways, in one pathway, lysine 2-ketoglutarate reductase results in the formation of saccharopine from lysine by extracting one amino group to be used as a nitrogen source. While in the second pathway the ω-aminotransferase converts D-lysine or L-lysine into 2-aminoadipic semialdehyde and 2-aminoadipic acid (homoglutamic acid). Both enzymes are prompted by L-lysine which is negatively regulated by NH4+ ions. The ω-aminotransferase from different species uses 2-ketoacids as amino group acceptors. The most common ones are 2-ketoadipate and 2-ketoglutarate resulting directly in the development of 2-aminoadipic acid and glutamic acid. We are agreed with the reviewer that ω--aminotransferase reaction which converts the alpha ketoadipic acid is into alpha-amino adipic acid is probably the best approach to obtain unexpansive AAA- The mechanism of action of the ω- aminotransferase is still poorly known but it could be explored.

Comments 7:

In the second part of the introduction, the author proposes to use the phenylalanine dehydrogenase from Thermoactinomyces to produce AAA from alpha ketoadipic. This is a surprising approach since the substrate of phenylalanine DH has 9 carbons aromatic substrate that is delaminated to phenylpyruvate; this reaction biochemically is quite different from that converting alpha-ketoadipate in AAA. The authors should clarify why they choose to use this reaction for the conversion but they do not approach the modification of enzymes related to the bacterial or fungal formation of AAA. The authors should give a clear study of the relative efficiency of AAA formation by the phenylalanine DH in relation to the natural enzymes forming AAA.

Response 7: We are thankful to the reviewer for this comment. We have chosen reductive amination reaction strategies for the production of homoglutamate by proposing the phenylalanine dehydrogenase from Thermoactinomyces using alpha ketoadipic which is an interesting route for the conversion of 2-ketoadipic acid catalyzed by NADH-dependent phenylalanine-dehydrogenase. The natural TiPDH enzyme affinity towards the transamination of 2-ketoadipic acid was previously found insufficient, therefore, we have chosen some amino acids sites in TiPDH and mutated which enhanced that catalytic activity for the production of AAA.

Comment 8:

Line 118 and in the Results section the authors indicate that the affinity of the TiPDH for transamination of the 2-cetoadipate substrate is insufficient and therefore they try to improve the production by mutagenesis of two amino acids of the putative active center. This observation indicates that this is not the best starting point for the development of the high production of AAA.

Response 8: We are obliged to the reviewer for this comment. In the introduction (line 111-116) and result section, we have modified the sentence in the track changes and highlighted it with red color according to the reviewer's suggestion.

Comment 9:

In Materials and Methods, the authors describe the quantification of AAA formation by HPLC but, as the authors indicate previously, homoglutamate (AAA) has not had good UV absorption and the method utilized is not clear. In all classical studies, amino acids are measured after derivatization with OPA or other UV emitting agents. Please indicate which is method used in this article.

Response 9: The authors are grateful to the reviewer for this comment. The method used in the article is explained in reference 36.

Comment 10:

In the Discussion section, the authors focus the discussion on the structure of the TiPDH and but they do not compare the active center of this enzyme with those of other alpha aminoadipic forming enzymes.

Response 10: We are obliged to the reviewer for raising this point. We have included some sentences of the revised manuscript (discussion section lines 454-456) which compared the active site domain of different alpha aminoadipic forming enzymes. We are the first to mutate the active site residues of TiPDH and no literature is available for comparing the active site of TiPDH with other alpha aminoadipic forming enzymes.

Comment 11:

The authors in line 142 give the accession number of the nucleotides sequence of the TiPDH encoding gene, D00631. However, since in the article, the authors constantly refer to the TiPDH protein the accession number of the protein should be easily accessible in the text. We found that the amino acids sequence shown in figure S2 does not correspond to the sequences published by Ohshima et al or Tanaka et al. Is it a different protein? Please clarify.

Response 11: We appreciate the reviewer for reviewing our article in deep. The Accession Number D00631 is for TiPDH which we used throughout the manuscript that can easily be assessable and can be recognized. The amino acid sequences in the S1 Figure are that of TiPDH. The protein sequences of TiPDH and those published by Oshima T and Takada H are the same proteins but from a different organism that has a resemblance in amino acid residues at the active site domain.

Comment 12:

In line 87 the authors refer to the work of Perez Llarena referring to an enzymatic reaction. This work is purely a description of gene sequences. The real work of purification and characterization of the enzyme in that of “de la Fuente et al., 1997”

Response 12: We are thankful to the reviewer for this comment. We are agreed with the reviewer that the reference of Perez Llarena is not for PDH enzymatic reaction, so in the revised manuscript we removed the Perez Llarena reference and replaced it with De la Fuente et al.,

Attachment

Submitted filename: Response to Reviwers.docx

Decision Letter 1

Israel Silman

20 Jan 2022

PONE-D-21-21697R1Engineering of Phenylalanine Dehydrogenase from Thermoactinomyces Intermedius for the Production of a novel HomoglutamatePLOS ONE

Dear Dr. Israr,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. In your revised manuscript please address in full the minor comments made by Reviewer 1.

Please submit your revised manuscript by Mar 06 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Israel Silman

Academic Editor

PLOS ONE

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: 1. In Fig. 1 a and 1 b , km and vmax units should be added.

2. For the effect of sucrose and trehalose , previous results on other enzymes are stronger, please discuss:

International journal of biological macromolecules 43 (2), 187-191, 2008.

3. Other variants of phenylalanine dehydrogenase have been reported and should be used

In introduction part: Archives of biochemistry and biophysics 635, 44-51, 2017

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2022 Mar 30;17(3):e0263784. doi: 10.1371/journal.pone.0263784.r004

Author response to Decision Letter 1


24 Jan 2022

Dear editor

We would like thanks to you and reviewers for their precious time to review our manuscript in deep and critically and for suggesting corrections that improved the quality of our manuscript. We are pleased to submit the revised manuscript entitled “Engineering of Phenylalanine Dehydrogenase from Thermoactinomyces Intermedius for the Production of a novel Homoglutamate” for consideration in PLOS ONE. On the following pages, you will find our response to the reviewer comments. The reviewer comments and suggestions are highlighted with red color and responses to each point with normal text. On behalf of my co-authors, I thank you for your consideration of this resubmission. We appreciate your time and look forward to your response.

Sincerely,

Dr. Muhammad Israr PhD, Postdoc (Corresponding Author)

Associate Professor, Department of Biology

The University of Haripur, KPK, Pakistan

Reviewers comments and Responses

Reviewer

Comment 1: In Fig. 1 a and 1 b, km and Vmax units should be added.

Response 1: We are grateful to the reviewer for pointing out this mistake. The units of Km and Vmax are added in the revised manuscript.

Comment 2:

For the effect of sucrose and trehalose, previous results on other enzymes are stronger, please discuss: International journal of biological macromolecules 43 (2), 187-191, 2008.

Response 2: Thanks for this comment. In line 404-406 of result part, we have added a sentence with reference for comparing the effect of osmolytes such as sucrose on the thermal stability of previously reported enzyme (firefly luciferase) with our results.

Comment 3:

Other variants of phenylalanine dehydrogenase have been reported and should be used

In introduction part: Archives of biochemistry and biophysics 635, 44-51, 2017

Response 3: We are obliged to the reviewer for this comment. In line 97-98 of introduction part, a reference for reporting phenylalanine dehydrogenase from Bacillus badius has added accordingly.

Attachment

Submitted filename: Response to Reviwers.docx

Decision Letter 2

Israel Silman

27 Jan 2022

Engineering of Phenylalanine Dehydrogenase from Thermoactinomyces Intermedius for the Production of a novel Homoglutamate

PONE-D-21-21697R2

Dear Dr. Israr,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Israel Silman

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Acceptance letter

Israel Silman

24 Feb 2022

PONE-D-21-21697R2

Engineering of Phenylalanine Dehydrogenase from Thermoactinomyces Intermedius for the Production of a novel Homoglutamate

Dear Dr. Israr:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Prof. Israel Silman

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Fig

    (a) Effect of PMSF on substrate decreased the residual enzyme activity. (b) Effect of different concentration of Trehalose and Sucrose showed protective effects in the stability of the enzyme.

    (DOCX)

    S2 Fig. TiPDH sequence containing thirteen α helices and twelve β strands sheets and some conserved regions.

    The red underlined K69, K81, and N264 are conserved residues and are involved in the binding of substrate. Whereas the highlighted residues encircled in the red boxes are involved in the binding of cofactors.

    (DOCX)

    S1 Table. Plasmids used in this work.

    (DOCX)

    S2 Table. Primers for wild type and mutant enzymes used in this study.

    (DOCX)

    S3 Table. Molecular docking statistics of α-Ketoadipic acid and Phenylalanine with the binding pocket of TiPDH.

    (DOCX)

    Attachment

    Submitted filename: Evaluation AAA.docx

    Attachment

    Submitted filename: Response to Reviwers.docx

    Attachment

    Submitted filename: Response to Reviwers.docx

    Data Availability Statement

    All relevant data are within the paper and its Supporting information files.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES